Clinical trials: Non-myeloid Malignancies
Acute Myeloid Leukemia (AML), Acute Myelocytic Leukemia
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
This research study is evaluating the safety and tolerability of the drug lenalidomide in combination with and following mismatched related donor microtransplantation in high risk AML patients in first remission.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Myelocytic Leukemia, Acute Myelogenous Leukemia, Acute Granulocytic Leukemia
- Trial name
- NCT02255162
- Testing
- Lenalidomide, HLA-mismatched stem-cell Microtransplantation, Cytarabine
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
PTCy and ATG for MSD and MUD Transplants
Hematopoietic stem cell transplantation is a curative treatment for a number of benign and malignant hematologic diseases. One of the key parts of hematopoietic stem cell transplantation is the prophylaxis of graft-versus-host…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma
- Trial name
- NCT06299462
- Testing
- ATG 5.0, Cyclophosphamide injection, ATG 4.0
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
This research study is for subjects that are receiving a bone marrow transplant. As part of the transplant subjects will receive stem cells from a donor who has agreed to donate stem cells for them.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- TAR (NCT01611298)
- Testing
- Tetanus
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Robert Krance
Leukemia, Chronic Myeloid
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
The aim of this study was to evaluate the real-world treatment patterns, healthcare resource use and costs among patients newly diagnosed with CML who were treated with tyrosine kinase inhibitors (TKIs) in first- and second-line…
- Trial name
- NCT07188428
- Where
- United States
- Volunteers
- 2,298 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy)…
- Conditions
- Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission, Myeloproliferative Syndrome
- Trial name
- HLA (NCT03852407)
- Testing
- Thymoglobulin, Melphalan, Fludarabine
- Where
- 10 sites in Belgium
- Volunteers
- 114 people
- Sponsor
- University of Liege
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source.
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
- Trial name
- NCT02581007
- Testing
- Fludarabine, Melphalan, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northside Hospital, Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
This clinical trial studies fludarabine phosphate, low-dose total body irradiation, and donor stem cell transplant in treating patients with hematologic malignancies or kidney cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00005799
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 7 sites in United States, Germany
- Volunteers
- 55 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005804
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Stem Cell Transplantation, Myelodysplastic Syndromes
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
The goal of this study is to test an electronic health (eHealth) mindfulness-based music therapy intervention to improve health-related quality of life and reduce symptom burden and disease activity in patients undergoing stem…
- Conditions
- Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT07469592
- Testing
- eHealth Mindfulness-based Music Therapy (eMBMT), eHealth Mindfulness Meditation (eMM)
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- University of Miami
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia
Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
The aim of the study is to improve the accuracy of diagnosis for children and adolescents with MDS by a standardized review of morphology and standardized cytogenetic and molecular analysis.
- Trial name
- EWOG MDS 2006 (NCT00662090)
- Where
- Germany
- Volunteers
- 260 people
- Sponsor
- University Hospital Freiburg
Leukemia
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045422
- Testing
- recombinant interferon alfa, imatinib mesylate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered…
- Conditions
- Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia, Relapsed or Refractory Myeloid Malignancies
- Trial name
- NCT02561988
- Testing
- Avapritinib
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 86 people
- Sponsor
- Blueprint Medicines Corporation
Leukemia, Lymphoma
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005946
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
This study is for patients with relapsed of disease after allogeneic bone marrow The donor's T cells are activated by exposure to 2 compounds or antibodies that bind (or stick to) two compounds on T cells called CD3 and CD28.
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00674427
- Testing
- CD3/CD28 Activated T cells
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pennsylvania
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
In-Vivo Activated T-Cell Depletion to Prevent GVHD
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00594308
- Testing
- Cyclophosphamide, Fludarabine, Cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Leukemia
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have chronic…
- Trial name
- NCT00006091
- Testing
- arsenic trioxide
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00691015
- Testing
- rituximab, busulfan, carmustine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute